Stay updated with breaking news from For Papers. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Capivasertib is indicated for hormone receptor-positive, human epidermal growth factor 2-negative locally advanced or metastatic breast cancer with 1 or more PIK3CA/ALT1/PTEN-alterations.
The approval makes enzalutamide the first and only androgen receptor-signaling inhibitor approved for the treatment of nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastatic.
Submissions are invited for Commonwealth Law Review Journal, Annual Volume 9 – 2023 Edition, Impact Factor 6.2, Google Scholar H-Index 14.Research Area: All of Law and related topics Submission...
JEE Main 2023 Application Form at jeemain.nta.nic.in: The correction window for JEE Main 2023 will remain open till January 14, 2023. -- aaa
Chandler, Arizona (PRWEB) September 01, 2022 -- Today, ADC Review | Journal of Antibody-drug Conjugates, a must-read peer-reviewed journal covering all